ALKERMES | ALKS - Cash And Equivalent



ALKERMES reported $521.2M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Acadia Pharmaceuticals USD 762M 80.42M Jun/2025
ALKERMES USD 521.2M 121.39M Jun/2025
Amgen USD 8.03B 782M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Merck USD 8.01B 622M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
Otsuka Holdings JPY 407.5B 18.68B Mar/2025
Pfizer USD 1.64B 208M Jun/2025
Regeneron Pharmaceuticals USD 2B 1.09B Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025